Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL.

PMID:30910786
Dieck CL , Ferrando AA
Blood
Mutations in the cytosolic 5' nucleotidase II () gene drive resistance to thiopurine chemotherapy in relapsed acute lymphoblastic leukemia (ALL). Mechanistically, NT5C2 mutant proteins have increased nucleotidase activity as a result of altered activating and autoregulatory switch-off mechanisms. Leukemia cells harboring activating mutations are chemo-resistant to 6-mercaptopurine (6-MP), yet show impaired proliferative and self-renewal capacity. Direct inhibition of NT5C2 or pharmacologic targeting of compensatory pathways active in mutant cells may antagonize the emergence of mutant clones driving resistance and relapse in ALL.


Copyright(C) 2006 BIOIMPACT Co., Ltd. All Rights Reserved